Phlow Launches Key Injectables To Alleviate Pediatric Shortages
As Company Continues Working Closely With Fresenius Kabi For Future Products
Phlow has announced the launch of key essential injectables for the Children’s Hospital Coalition to help prevent pediatric drug shortages, as CEO Eric Edwards told Generics Bulletin that Phlow is becoming a commercial end-to-end company and a fully integrated contract development and manufacturing organization.
You may also be interested in...
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.
Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.
British Columbia has added three new biosimilar versions of the anti-clotting drug enoxaparin to PharmaCare, including Redesca, Noromby and Inclunox. The move comes after the Canadian province recently included additional biosimilars in its switching program.